SpinePoint Medical is anticipating a 2025 launch for what it describes as the lowest stiffness interbody cages on the market.
SpinePoint expects its first FDA marketing clearance in mid-2024 for solutions to address implant failures and revision surgeries. The company’s proprietary technology is designed to produce the lowest stiffness cages on the market. Using a patented Z shape, the devices allow microcushioning to reduce subsidence and adjacent level stresses.
The first product to market will be the lowest stiffness cervical cage available, offering flexibility and support for optimal fusion and stability in cervical spine surgeries.
Following the introduction of the cervical cage, SpinePoint plans to release seven additional products utilizing the same patented Z shape design. This design enables a spring-like action that accommodates the natural movements of the entire spine, regardless of the surgical approach.
In the pipeline is also a pedicle screw that can go around corners, allowing for unparalleled construct properties vs. conventional techniques.
SpinePoint is currently seeking $8.5 million Series A funding to complete commercialization goals.
“At SpinePoint, we are driven by a passion for improving the lives of patients suffering from spinal conditions,” said Dr. Lali Sekhon, Founder and Chief Medical Officer of SpinePoint Medical. “Our innovative approach combines state-of-the-art technology with surgical expertise to empower surgeons to solve the problems surgeons see with devices currently on the market and transform the landscape of spine care.”
SpinePoint Medical is anticipating a 2025 launch for what it describes as the lowest stiffness interbody cages on the market.
SpinePoint expects its first FDA marketing clearance in mid-2024 for solutions to address implant failures and revision surgeries. The company’s proprietary technology is designed to produce the lowest stiffness cages...
SpinePoint Medical is anticipating a 2025 launch for what it describes as the lowest stiffness interbody cages on the market.
SpinePoint expects its first FDA marketing clearance in mid-2024 for solutions to address implant failures and revision surgeries. The company’s proprietary technology is designed to produce the lowest stiffness cages on the market. Using a patented Z shape, the devices allow microcushioning to reduce subsidence and adjacent level stresses.
The first product to market will be the lowest stiffness cervical cage available, offering flexibility and support for optimal fusion and stability in cervical spine surgeries.
Following the introduction of the cervical cage, SpinePoint plans to release seven additional products utilizing the same patented Z shape design. This design enables a spring-like action that accommodates the natural movements of the entire spine, regardless of the surgical approach.
In the pipeline is also a pedicle screw that can go around corners, allowing for unparalleled construct properties vs. conventional techniques.
SpinePoint is currently seeking $8.5 million Series A funding to complete commercialization goals.
“At SpinePoint, we are driven by a passion for improving the lives of patients suffering from spinal conditions,” said Dr. Lali Sekhon, Founder and Chief Medical Officer of SpinePoint Medical. “Our innovative approach combines state-of-the-art technology with surgical expertise to empower surgeons to solve the problems surgeons see with devices currently on the market and transform the landscape of spine care.”
Copy to clipboard 
